Fig 1.
Markov chain model with seven CVID health states.
CLD, chronic lung disease (including bronchiectasis).
Fig 2.
Markov trace on mortality in the control and the intervention groups.
X-axis = cycle, from first to last (600). Y-axis = cumulative number of deaths. Dead_IgG = cumulative number of deaths in the intervention group (mean literature-based-dose IgGRT). Dead_Comp = cumulative number of deaths in the control group (zero-to-low-dose IgGRT).
Table 1.
Health effects in the base-case scenario.
Fig 3.
Cost-effectiveness planes for IgGRT.
A. Costs versus LYs. B. Costs versus QALYs.
Fig 4.
The difference in health outcome between the three simulated cohorts.
Intervention group: 1,000 simulated patients treated with a mean literature-based-dose of IgGRT (≥450 mg/kg/4 weeks); delayed intervention group (4 years): The first 48-months cycles of the intervention group were replaced by the values of the control group; control group: 1,000 simulated patients treated with zero-to-low-dose IgGRT regimens (0 to ≤100 mg/kg/4 weeks). Y-axis: Years gained. LYs, Life-years; QALYs, Quality-adjusted Life-years.
Table 2.
Health effects in the 4-year diagnostic delay scenario.